Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

This study has been completed.
Sponsor:
Information provided by:
Saitama Medical University
ClinicalTrials.gov Identifier:
NCT00530595
First received: September 13, 2007
Last updated: September 14, 2007
Last verified: September 2007

September 13, 2007
September 14, 2007
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00530595 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients
Not Provided

Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death. Although angiotensin receptor blockers (ARBs) are effective for patients with diabetes and chronic kidney disease in reducing or preventing cardiovascular diseases, there has been no decisive study that demonstrated treatment with ARBs is effective in patients on HD.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Cardiovascular Disease
Drug: candesartan or valsartan or losartan
Not Provided
Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):501-6. Epub 2008 Jul 24.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • 30 to 80 years of age
  • Receiving hemodialysis at least 12 months and less than 5 years
  • Pre-dialysis systolic blood pressure was more than 160 mmHg, or more than 150 mmHg if the patients received antihypertensive agents.

Exclusion Criteria:

  • Use of angiotensin receptor blocker or angiotensin converting enzyme inhibitor
Both
30 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00530595
S-01
No
Not Provided
Saitama Medical University
Not Provided
Study Director: Hiromichi Suzuki, MD, PhD Department of Nephrology, Saitama Medical University
Saitama Medical University
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP